<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120523</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981C2306</org_study_id>
    <nct_id>NCT00120523</nct_id>
  </id_info>
  <brief_title>5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in
      the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than
      12 months of age compared to topical corticosteroids (TCS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessed by Adverse Events</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>crude incidence of adverse events of primary interest and most frequent adverse events (greater than or equal to 5% crude incidence in either treatment group) in the treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth Velocity (Height)</measure>
    <time_frame>throughout the 5-year study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth Velocity (Weight)</measure>
    <time_frame>throughout the 5-year study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential Effect on the Developing Immune System</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>number (%) of patients with positive antibody titers to tetanus, hepatitis B, and measles vaccines at baseline, weeks 26 (6 months), 52 (1 year), 104 (2 years), 156 (3 years), 208 (4 years) and 260 (5 years) Varicella antibody titers were measured at the above time points in US patients only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (to Assess Disease Severity) of the Whole Body and of the Face: Treatment Success Rate</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>IGA = Investigator's global Assessment. CI = Confidence interval for treatment success using binomial distribution: lower CI&lt;0 is set to 0, upper CI&gt;100 is set to 100.
Treatment success (n): IGA score of 0 or 1 (clear or almost clear). Outcome gives percentage of patients with treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface Area Involved With Atopic Dermatitis</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>TBSA = Total body surface area; percent BSA affected = (BSA affected/TBSA) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent's Index of Quality of Life - Atopic Dermatitis (PIQoL-AD)</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>PIQoL-AD questionnaire (28 questions) was only done in countries where validated questionnaire was available: Germany, Hungary, Netherlands, Spain, UK and US.
For the purposes of data presentation, a &quot;Not True&quot; response was coded a value of zero and a &quot;True&quot; a value of one. The total score (i.e., sum of individual questions) was calculated; lower the score, better the QoL. Minimum score = 0; maximum score = 28. If the patient has answered ≤14 questions at a time point, then the patient's total score at the time point was set to missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs and Physical Examinations: Blood Pressure (BP)</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>Significant findings are included in the relevant medical history/current medical conditions (prior to study start) or in the AE documentation (after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs and Physical Examinations: Pulse</measure>
    <time_frame>throughout the 5-year study</time_frame>
    <description>Significant findings are included in the relevant medical history/current medical conditions (prior to study start) or in the AE documentation (after study start.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2418</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pimecrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <description>Pimecrolimus cream 1 %</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Elidel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical corticosteroids</intervention_name>
    <description>TCS</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 3 to &lt; 12 months

          -  Diagnosis of AD fulfilling the diagnostic criteria of Seymour

          -  AD affecting at least 5% total body surface area

          -  Investigator's Global Assessment (IGA) score of 2 or 3, corresponding to
             mild-to-moderate disease at baseline

          -  Informed consent

        Exclusion Criteria:

          -  Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic
             corticosteroids within 4 weeks

          -  Topical tacrolimus or pimecrolimus within 2 weeks

          -  Topical therapy (e.g., tar, topical corticosteroids) within 3 days

          -  Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history
             of malignant disease

          -  Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox),
             and/or clinically infected AD

          -  Failure to thrive (e.g., weight or height/length below the 5th percentile) or
             developmental abnormalities such as head circumference less than 5th and more than
             95th percentile

          -  Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical
             corticosteroids

          -  Clinical conditions other than AD that according to investigator can interfere with
             the evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cholla Pediatrics</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Pediatric Clinic</name>
      <address>
        <city>Little Rock,</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Allergy &amp; Asthma Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9540 Artesia Blvd., Suite #1</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Care Medical Group, Inc.</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longmont Clinical Research</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Skin Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Research Center of South Florida</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AeroAllergy Research Laboratories of Savanah, Inc.</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pediatric Center</name>
      <address>
        <city>Stone Mountain</city>
        <state>Georgia</state>
        <zip>30083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University Dermatology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University - Kalamazoo Center for Med Studies</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Research Institute of Michigan</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMDC Health System</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Center for Children</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Dept. of Dermatology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Rochester, P.C.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Pediatrics &amp; Adolescent Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>245230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatrics, Inc.</name>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Portland Clinic</name>
      <address>
        <city>Beaverton</city>
        <state>Oregon</state>
        <zip>97006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calcagno Research and Development</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Consultants, LLP</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergic Disease and Asthma Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee - Dept. of Pediatrics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce&amp; Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Parkway Pediatrics</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Investigative Site</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2005</study_first_posted>
  <results_first_submitted>November 9, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2013</results_first_posted>
  <disposition_first_submitted>August 23, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 23, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 25, 2011</disposition_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis, children, infants, pimecrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient was enrolled into the study on 05 Apr 2004, last patient completed on 04 Oct 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pimecrolimus</title>
          <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
        </group>
        <group group_id="P2">
          <title>Topical Corticosteroids</title>
          <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1205"/>
                <participants group_id="P2" count="1213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="836"/>
                <participants group_id="P2" count="874"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="369"/>
                <participants group_id="P2" count="339"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-Up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120">Patients discontinued due to lost to follow-up or who withdrew consent were not part of this period.</participants>
                <participants group_id="P2" count="70">Patients discontinued due to lost to follow-up or who withdrew consent were not part of this period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pimecrolimus</title>
          <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
        </group>
        <group group_id="B2">
          <title>Topical Corticosteroids</title>
          <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1205"/>
            <count group_id="B2" value="1213"/>
            <count group_id="B3" value="2418"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1205"/>
                    <measurement group_id="B2" value="1213"/>
                    <measurement group_id="B3" value="2418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="2.71"/>
                    <measurement group_id="B2" value="7.1" spread="2.66"/>
                    <measurement group_id="B3" value="7.1" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="461"/>
                    <measurement group_id="B2" value="471"/>
                    <measurement group_id="B3" value="932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="744"/>
                    <measurement group_id="B2" value="742"/>
                    <measurement group_id="B3" value="1486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecuador</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guatemala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iceland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Assessed by Adverse Events</title>
        <description>crude incidence of adverse events of primary interest and most frequent adverse events (greater than or equal to 5% crude incidence in either treatment group) in the treatment period</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>complete safety/ITT population of experimental and control</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>Pimecrolimus 1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country's label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessed by Adverse Events</title>
          <description>crude incidence of adverse events of primary interest and most frequent adverse events (greater than or equal to 5% crude incidence in either treatment group) in the treatment period</description>
          <population>complete safety/ITT population of experimental and control</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1205"/>
                <count group_id="O2" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute tonsillitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergy to arthropod bite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthropod bite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchiolitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchospasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis allergic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dermatitis diaper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eczema infected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Food allergy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroenteritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroenteritis viral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heat rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunisation reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impetigo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza like illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laryngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molluscum contagiosum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasopharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis media</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis media acute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinitis allergic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Teething</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tonsillitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Growth Velocity (Height)</title>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) – all randomized patients who received at least one application of study medication.Patient who do not have a baseline value are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>Pimecrolimus 1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country's label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Velocity (Height)</title>
          <population>Safety/intent-to-treat (ITT) – all randomized patients who received at least one application of study medication.Patient who do not have a baseline value are excluded from the analysis.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1204"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1204, n=1208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="5.26"/>
                    <measurement group_id="O2" value="68.8" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=1144, n=1141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="4.82"/>
                    <measurement group_id="O2" value="71.3" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=1092, n=1114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="4.37"/>
                    <measurement group_id="O2" value="76.9" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=999, n=1052)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="4.23"/>
                    <measurement group_id="O2" value="83.1" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=924, n=975)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" spread="4.31"/>
                    <measurement group_id="O2" value="92.9" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=871, n=919)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.5" spread="4.70"/>
                    <measurement group_id="O2" value="100.6" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 (n=843, n=869)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.7" spread="5.46"/>
                    <measurement group_id="O2" value="107.8" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=833, n=871)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.4" spread="5.26"/>
                    <measurement group_id="O2" value="114.5" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Growth Velocity (Weight)</title>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.Patient who do not have a baseline value are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>Pimecrolimus 1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country's label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Velocity (Weight)</title>
          <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.Patient who do not have a baseline value are excluded from the analysis.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1203"/>
                <count group_id="O2" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1203, n=1213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="1.51"/>
                    <measurement group_id="O2" value="8.2" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=1144, n=1144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="1.45"/>
                    <measurement group_id="O2" value="8.7" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=1093, n=1114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.43"/>
                    <measurement group_id="O2" value="10.1" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=1003, n=1054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="1.52"/>
                    <measurement group_id="O2" value="11.6" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=928, n=978)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="1.90"/>
                    <measurement group_id="O2" value="14.1" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=873, n=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="2.32"/>
                    <measurement group_id="O2" value="16.3" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 (n=843, n=870)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="2.80"/>
                    <measurement group_id="O2" value="18.7" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=833, n=871)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="3.51"/>
                    <measurement group_id="O2" value="21.4" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator's Global Assessment (to Assess Disease Severity) of the Whole Body and of the Face: Treatment Success Rate</title>
        <description>IGA = Investigator's global Assessment. CI = Confidence interval for treatment success using binomial distribution: lower CI&lt;0 is set to 0, upper CI&gt;100 is set to 100.
Treatment success (n): IGA score of 0 or 1 (clear or almost clear). Outcome gives percentage of patients with treatment success.</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Assessment (to Assess Disease Severity) of the Whole Body and of the Face: Treatment Success Rate</title>
          <description>IGA = Investigator's global Assessment. CI = Confidence interval for treatment success using binomial distribution: lower CI&lt;0 is set to 0, upper CI&gt;100 is set to 100.
Treatment success (n): IGA score of 0 or 1 (clear or almost clear). Outcome gives percentage of patients with treatment success.</description>
          <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1205"/>
                <count group_id="O2" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall IGA Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="58.5" upper_limit="64.2"/>
                    <measurement group_id="O2" value="59.6" lower_limit="56.8" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall IGA Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" lower_limit="63.6" upper_limit="69.2"/>
                    <measurement group_id="O2" value="74.5" lower_limit="71.9" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall IGA Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="71.2" upper_limit="76.6"/>
                    <measurement group_id="O2" value="79.6" lower_limit="77.2" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall IGA Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" lower_limit="77.3" upper_limit="82.4"/>
                    <measurement group_id="O2" value="83.4" lower_limit="81.0" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall IGA Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="79.3" upper_limit="84.4"/>
                    <measurement group_id="O2" value="86.1" lower_limit="83.9" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall IGA Week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="83.8" upper_limit="88.5"/>
                    <measurement group_id="O2" value="88.1" lower_limit="86.0" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall IGA Week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="86.6" upper_limit="90.9"/>
                    <measurement group_id="O2" value="92.3" lower_limit="90.5" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="66.3" upper_limit="71.6"/>
                    <measurement group_id="O2" value="71.0" lower_limit="68.4" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="77.1" upper_limit="81.9"/>
                    <measurement group_id="O2" value="83.8" lower_limit="81.6" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" lower_limit="83.4" upper_limit="87.7"/>
                    <measurement group_id="O2" value="88.5" lower_limit="86.6" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="90.4" upper_limit="93.9"/>
                    <measurement group_id="O2" value="94.1" lower_limit="92.6" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="92.6" upper_limit="95.7"/>
                    <measurement group_id="O2" value="94.3" lower_limit="92.8" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="94.7" upper_limit="97.3"/>
                    <measurement group_id="O2" value="96.2" lower_limit="95.0" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial IGA Week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="95.4" upper_limit="97.9"/>
                    <measurement group_id="O2" value="97.2" lower_limit="96.2" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Surface Area Involved With Atopic Dermatitis</title>
        <description>TBSA = Total body surface area; percent BSA affected = (BSA affected/TBSA) x 100.</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Surface Area Involved With Atopic Dermatitis</title>
          <description>TBSA = Total body surface area; percent BSA affected = (BSA affected/TBSA) x 100.</description>
          <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.</population>
          <units>percentage of TBSA affected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1205"/>
                <count group_id="O2" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=1205, n=1213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="16.50"/>
                    <measurement group_id="O2" value="21.3" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=1142, n=1138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="8.72"/>
                    <measurement group_id="O2" value="6.0" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=1091, n=1113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="8.30"/>
                    <measurement group_id="O2" value="3.7" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=997, n=1048)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="7.69"/>
                    <measurement group_id="O2" value="2.7" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=922, n=975)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="6.53"/>
                    <measurement group_id="O2" value="1.8" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=871, n=918)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="5.46"/>
                    <measurement group_id="O2" value="1.4" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 (n=843, n=868)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="5.16"/>
                    <measurement group_id="O2" value="1.2" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=833, n=870)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.31"/>
                    <measurement group_id="O2" value="0.9" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parent's Index of Quality of Life - Atopic Dermatitis (PIQoL-AD)</title>
        <description>PIQoL-AD questionnaire (28 questions) was only done in countries where validated questionnaire was available: Germany, Hungary, Netherlands, Spain, UK and US.
For the purposes of data presentation, a “Not True” response was coded a value of zero and a “True” a value of one. The total score (i.e., sum of individual questions) was calculated; lower the score, better the QoL. Minimum score = 0; maximum score = 28. If the patient has answered ≤14 questions at a time point, then the patient’s total score at the time point was set to missing.</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication. Patients who do not have baseline value are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>Pimecrolimus 1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country's label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Parent's Index of Quality of Life - Atopic Dermatitis (PIQoL-AD)</title>
          <description>PIQoL-AD questionnaire (28 questions) was only done in countries where validated questionnaire was available: Germany, Hungary, Netherlands, Spain, UK and US.
For the purposes of data presentation, a “Not True” response was coded a value of zero and a “True” a value of one. The total score (i.e., sum of individual questions) was calculated; lower the score, better the QoL. Minimum score = 0; maximum score = 28. If the patient has answered ≤14 questions at a time point, then the patient’s total score at the time point was set to missing.</description>
          <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication. Patients who do not have baseline value are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=406, n=405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.04"/>
                    <measurement group_id="O2" value="8.4" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=378, n=360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="4.76"/>
                    <measurement group_id="O2" value="6.0" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=368, n=363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.73"/>
                    <measurement group_id="O2" value="5.0" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=327, n=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="4.45"/>
                    <measurement group_id="O2" value="4.4" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=302, n=296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.69"/>
                    <measurement group_id="O2" value="3.9" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (n=269, n=266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="4.67"/>
                    <measurement group_id="O2" value="3.4" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 (n=254, n=256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.93"/>
                    <measurement group_id="O2" value="3.0" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=249, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.22"/>
                    <measurement group_id="O2" value="2.3" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs and Physical Examinations: Blood Pressure (BP)</title>
        <description>Significant findings are included in the relevant medical history/current medical conditions (prior to study start) or in the AE documentation (after study start.</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.Patients who do not have baseline value are excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs and Physical Examinations: Blood Pressure (BP)</title>
          <description>Significant findings are included in the relevant medical history/current medical conditions (prior to study start) or in the AE documentation (after study start.</description>
          <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.Patients who do not have baseline value are excluded from analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1205"/>
                <count group_id="O2" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" spread="12.40"/>
                    <measurement group_id="O2" value="94.7" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" spread="11.70"/>
                    <measurement group_id="O2" value="96.3" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="11.46"/>
                    <measurement group_id="O2" value="98.4" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" spread="11.33"/>
                    <measurement group_id="O2" value="99.3" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" spread="10.01"/>
                    <measurement group_id="O2" value="97.9" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" spread="9.47"/>
                    <measurement group_id="O2" value="98.6" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" spread="10.10"/>
                    <measurement group_id="O2" value="99.4" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP- Week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="9.51"/>
                    <measurement group_id="O2" value="100.1" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="10.40"/>
                    <measurement group_id="O2" value="59.1" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="9.47"/>
                    <measurement group_id="O2" value="61.0" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="9.90"/>
                    <measurement group_id="O2" value="61.6" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="9.12"/>
                    <measurement group_id="O2" value="61.9" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" spread="8.14"/>
                    <measurement group_id="O2" value="61.7" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" spread="8.11"/>
                    <measurement group_id="O2" value="62.0" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" spread="8.52"/>
                    <measurement group_id="O2" value="61.8" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP - Week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="7.24"/>
                    <measurement group_id="O2" value="62.2" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Potential Effect on the Developing Immune System</title>
        <description>number (%) of patients with positive antibody titers to tetanus, hepatitis B, and measles vaccines at baseline, weeks 26 (6 months), 52 (1 year), 104 (2 years), 156 (3 years), 208 (4 years) and 260 (5 years) Varicella antibody titers were measured at the above time points in US patients only.</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Immune system function data analyses were performed on the immunology set (774 patients). Varicella titers were assessed for USA patients only (n= 104, n=108).</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>Pimecrolimus 1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country's label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Potential Effect on the Developing Immune System</title>
          <description>number (%) of patients with positive antibody titers to tetanus, hepatitis B, and measles vaccines at baseline, weeks 26 (6 months), 52 (1 year), 104 (2 years), 156 (3 years), 208 (4 years) and 260 (5 years) Varicella antibody titers were measured at the above time points in US patients only.</description>
          <population>Immune system function data analyses were performed on the immunology set (774 patients). Varicella titers were assessed for USA patients only (n= 104, n=108).</population>
          <units>% of patients with positive ab titer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tetanus Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5"/>
                    <measurement group_id="O2" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5"/>
                    <measurement group_id="O2" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                    <measurement group_id="O2" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3"/>
                    <measurement group_id="O2" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                    <measurement group_id="O2" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1"/>
                    <measurement group_id="O2" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1"/>
                    <measurement group_id="O2" value="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs and Physical Examinations: Pulse</title>
        <description>Significant findings are included in the relevant medical history/current medical conditions (prior to study start) or in the AE documentation (after study start.</description>
        <time_frame>throughout the 5-year study</time_frame>
        <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.Patients who do not have baseline value are excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus</title>
            <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
          </group>
          <group group_id="O2">
            <title>Topical Corticosteroids</title>
            <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs and Physical Examinations: Pulse</title>
          <description>Significant findings are included in the relevant medical history/current medical conditions (prior to study start) or in the AE documentation (after study start.</description>
          <population>Safety/intent-to-treat (ITT) - all randomized patients who received at least one application of study medication.Patients who do not have baseline value are excluded from analysis.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1205"/>
                <count group_id="O2" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.7" spread="19.43"/>
                    <measurement group_id="O2" value="116.0" spread="19.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.2" spread="18.19"/>
                    <measurement group_id="O2" value="114.5" spread="19.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.4" spread="18.09"/>
                    <measurement group_id="O2" value="111.7" spread="18.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.7" spread="18.63"/>
                    <measurement group_id="O2" value="107.0" spread="17.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.7" spread="15.97"/>
                    <measurement group_id="O2" value="101.8" spread="15.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="13.45"/>
                    <measurement group_id="O2" value="97.0" spread="13.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" spread="12.78"/>
                    <measurement group_id="O2" value="93.4" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" spread="12.82"/>
                    <measurement group_id="O2" value="90.4" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the study period of 5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pimecrolimus</title>
          <description>1% cream was supplied in 50 g tubes by the sponsor. Elidel was to be applied as a thin layer to the affected skin b.i.d., and rubbed in gently and completely by the primary caregiver</description>
        </group>
        <group group_id="E2">
          <title>Topical Corticosteroids</title>
          <description>Low or medium potency (low potency, e.g. Hydrocortisone acetate; or medium potency, e.g.
Fluticasone propionate)TCS supplied locally were to be used according to the country’s label as study medication for patients randomized to TCS group. Topical corticosteroids were to be applied as a thin layer to the affected skin only and rubbed in gently.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Acute chest syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhytmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Atrioventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hereditary fructose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amblyopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Disbacteriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Perianal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Vaccination site hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Croup infections</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Subcutaneous abcess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Alpha haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Application site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bacterial rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis astroviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hepatitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Kaposi's varicelliform eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Laryngotracheitis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Meningococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Naspoharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia adenoviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Accidential drug intake by child</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Conjunctival abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Rotavirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Ependymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Post-traumatic headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Speech disorder developmental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tongue biting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Autism spectrum disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Penile adhesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Sleep apnoe syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchial obstuction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Mouth breathing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1162" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="1160" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="384" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="381" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="589" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="605" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Immunisation reaction</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="711" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="715" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="438" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="410" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="418" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="385" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="378" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="340" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="329" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="284" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="231" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropode bite</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="369" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="1213"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1205"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research</name_or_title>
      <organization>MEDA Pharma GmbH &amp; Co. KG</organization>
      <phone>+49 6172 888 ext 01</phone>
      <email>clinical.research@medapharma.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

